![]() |
市場調查報告書
商品編碼
2087656
泌尿系統醫療設備市場:2026-2032年全球市場預測(依產品類型、技術、用途、病患類型、材料、應用、最終用戶和分銷管道分類)Urology Devices Market by Product Type, Technology, Usage Type, Patient Type, Material, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,泌尿系統醫療設備市場將成長至 564.7 億美元,複合年成長率為 8.20%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 325.2億美元 |
| 預計年份:2026年 | 348.2億美元 |
| 預測年份 2032 | 564.7億美元 |
| 複合年成長率 (%) | 8.20% |
泌尿系統醫療設備市場正受到人口老化以及泌尿系統併發症診斷數量增加的影響,這些併發症包括尿道結石、良性前列腺增生、尿失禁、前列腺癌、膀胱癌、慢性腎臟病和醫院感染。檢驗臨床和公共衛生驗證的證據表明,這些疾病與診斷性泌尿系統、內視鏡泌尿系統、排尿功能管理、透析通路支持和腫瘤泌尿系統等領域的診療需求增加有關。
微創泌尿系統醫療設備、泌尿系統內視鏡、體外碎石醫療設備、尿道導管、尿動力學系統、雷射系統、支架、導管導引線和機器人輔助手術平台的需求尤其旺盛。在檢驗的診療路徑中使用,這些器械能夠縮短住院時間、加快康復速度、提高手術精準度並降低感染風險。
競爭格局正從傳統的可重複使用器械轉向利用數位技術的、一次性使用的、針對特定手術的泌尿系統解決方案。在那些將感染控制、再處理能力、交叉感染風險和可預測的器械性能作為採購優先事項的領域,一次性輸尿管鏡和膀胱鏡正日益受到關注。
人工智慧(AI)正逐漸成為泌尿系統各個領域的累積驅動力,包括診斷、治療方案製定、手術室工作流程和術後監測。當基於臨床證據檢驗人工智慧成像技術並在醫生指導下使用時,它可以輔助病灶識別、結石定性、前列腺評估、腎臟影像解讀和工作流程標準化。
北美憑藉其先進的醫院基礎設施、龐大的手術量、完善的醫保報銷體系、廣泛的專科醫療服務以及機器人輔助泌尿系統手術、雷射技術、一次性內視鏡、尿動力學診斷和門診泌尿系統手術的快速普及,仍然是領先的市場區域。在歐洲,歐盟醫療設備法規 (MDR) 的審查流程、臨床證據要求、基於價值的採購 (VBP) 以及德國、法國、義大利、西班牙和英國對內視鏡、碎石、泌尿功能管理和癌症相關泌尿系統醫療設備的強勁需求,都在影響著市場。
歐盟高度重視監管合規性、臨床證據、上市後監管、可追溯性和永續採購,因此,對於泌尿系統醫療設備供應商而言,獲得CE認證的創新產品以及符合歐盟醫療器材法規(MDR)的要求至關重要。在七國集團(G7)國家,安全性、治療效果和療效均經過驗證的高階泌尿系統醫療設備更受青睞。同時,在北約成員國,供應穩定性、網路安全、醫療技術採購的連續性以及應對物流中斷的能力在採購環境中也變得日益重要。
美國在創新、FDA批准的醫療設備、機器人輔助手術、雷射碎石術以及門診泌尿系統治療的廣泛應用方面發揮主導作用。同時,加拿大在其公共醫療保健系統中強調實證醫學的採購、安全性和公平性取得。墨西哥和巴西透過投資私立醫院、拓展泌尿系統專科以及提高腎結石、良性前列腺增生(BPH)、尿失禁和泌尿器官系統癌症的診斷率,推動拉丁美洲地區的發展。
產業領導者應優先考慮在一次性內視鏡、結石管理、導尿管安全、雷射系統、尿動力學診斷、良性前列腺增生 (BPH) 治療以及數位互聯泌尿系統平台等領域打造差異化產品系列。商業性成功取決於能否證明臨床療效、降低總治療成本、支持感染預防,以及使產品設計與醫院工作流程和門診模式相契合。
本執行摘要基於系統的調查方法,結合了二次調查、監管審查、臨床指南評估、產品核可追蹤、保險報銷趨勢、行業數據、同行評審證據、公共衛生指標和醫療保健基礎設施分析。
泌尿系統醫療設備市場正進入一個以微創治療、數位整合、感染預防和擴大專科治療覆蓋範圍為特徵的新階段。醫療設備將繼續在醫院、專科診所和門診手術中心佔據主導地位。
The Urology Devices Market is projected to grow by USD 56.47 billion at a CAGR of 8.20% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 32.52 billion |
| Estimated Year [2026] | USD 34.82 billion |
| Forecast Year [2032] | USD 56.47 billion |
| CAGR (%) | 8.20% |
The urology devices market is being shaped by aging populations, higher diagnosis of urinary stone disease, benign prostatic hyperplasia, urinary incontinence, prostate cancer, bladder cancer, chronic kidney disease, and hospital-acquired urinary tract complications. Verified clinical and public health evidence links these conditions to increasing procedural demand across diagnostic urology, endourology, continence care, dialysis access support, and oncologic urology.
Demand is strongest for minimally invasive urology devices, urological endoscopes, stone management devices, urinary catheters, urodynamic systems, laser systems, stents, guidewires, and robotic-assisted surgical platforms that support shorter hospital stays, faster recovery, improved procedural precision, and lower infection risk when used within validated care pathways.
The competitive landscape is shifting from conventional reusable instruments toward digitally enabled, single-use, and procedure-specific urology solutions. Single-use ureteroscopes and cystoscopes are gaining traction where infection control, reprocessing capacity, cross-contamination risk, and predictable device performance are procurement priorities.
At the same time, thulium fiber lasers, high-power holmium lasers, advanced imaging, suction-assisted stone removal, antimicrobial and hydrophilic catheter materials, urodynamic workflow automation, and ambulatory surgery center adoption are changing how urologic care is delivered across hospitals and outpatient settings. These shifts are supported by clinical preferences for minimally invasive treatment, shorter recovery times, and evidence-based device selection.
Artificial intelligence is becoming a cumulative enabler across diagnosis, treatment planning, operating room workflow, and post-procedure monitoring in urology. AI-assisted imaging can support lesion recognition, stone characterization, prostate assessment, kidney imaging interpretation, and workflow standardization when validated against clinical evidence and used under physician oversight.
The strongest near-term value is expected in decision support, predictive maintenance, inventory optimization, procedure documentation, surgical video analytics, and patient risk stratification. Adoption will depend on FDA and EU MDR compliance, cybersecurity, interoperability with hospital systems, algorithm explainability, bias management, and clinician trust in real-world performance.
North America remains a leading region due to advanced hospital infrastructure, high procedural volumes, established reimbursement pathways, strong specialty access, and rapid adoption of robotic urology surgery, lasers, single-use scopes, urodynamic diagnostics, and outpatient urology procedures. Europe is influenced by EU MDR scrutiny, clinical evidence requirements, value-based purchasing, and strong demand across Germany, France, Italy, Spain, and the United Kingdom for endoscopy, stone treatment, continence care, and cancer-related urology devices.
Asia-Pacific is expanding through healthcare investment in China, India, Japan, South Korea, Australia, and ASEAN markets, supported by aging populations, rising diagnosis of kidney stones, BPH, prostate cancer, and chronic kidney disease, and broader access to tertiary care. Latin America is led by Brazil and Mexico, where private hospital investment supports adoption of minimally invasive devices despite uneven public-private access. The Middle East, especially GCC markets, is investing in specialty hospitals, digital health, and advanced surgical platforms, while Africa shows long-term need for affordable urinary catheters, endoscopes, stone treatment tools, and essential urologic care infrastructure.
The European Union emphasizes regulatory compliance, clinical evidence, post-market surveillance, traceability, and sustainable procurement, making CE-marked innovation and EU MDR readiness critical for urology device suppliers. G7 markets favor premium urology devices with documented safety, procedural efficiency, and outcome benefits, while NATO-aligned procurement environments increasingly prioritize supply security, cybersecurity, continuity of medical technology sourcing, and resilience against logistics disruption.
BRICS countries are central to volume-based demand because China, India, Brazil, Russia, and South Africa combine large patient pools with expanding hospital capacity and rising diagnosis of urologic conditions. ASEAN markets are scaling access through urban specialty centers, regional hospital upgrades, and greater availability of endourology services, while GCC countries are accelerating adoption of advanced urology platforms through public healthcare modernization, medical tourism initiatives, and specialty surgical investment.
The United States leads in innovation, FDA-cleared devices, robotic-assisted surgery, laser lithotripsy, and outpatient urology adoption, while Canada emphasizes evidence-based procurement, safety, and equitable access across public health systems. Mexico and Brazil support Latin American momentum through private hospital investment, urology specialty expansion, and rising diagnosis of kidney stones, BPH, urinary incontinence, and urologic cancers.
In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central for urological endoscopy, laser systems, urinary catheters, BPH therapy, urodynamics, and cancer-related urology care, while Russia maintains demand for essential and advanced devices despite procurement complexity and supply constraints. China and India provide large-scale procedural demand supported by hospital infrastructure development and growing specialist capacity; Japan and South Korea favor advanced technology, precision instruments, and high-quality surgical care; and Australia combines guideline-driven practice, specialty access, and adoption of minimally invasive urology devices.
Industry leaders should prioritize differentiated portfolios across single-use endoscopy, stone management, catheter safety, laser systems, urodynamic diagnostics, BPH therapy, and digitally connected urology platforms. Commercial success depends on proving clinical outcomes, reducing total procedure cost, supporting infection prevention, and aligning product design with hospital workflow and outpatient care models.
Manufacturers should localize pricing, training, service, and regulatory strategies by region; build AI governance early; strengthen supply resilience; and expand physician education through simulation, remote proctoring, digital training modules, and data-backed evidence packages for hospitals and ambulatory surgery centers. Partnerships with clinicians, payers, and procurement teams can improve adoption where devices demonstrate safety, efficiency, and measurable patient benefit.
This executive summary is based on a structured research methodology combining secondary research, regulatory review, clinical guideline assessment, product approval tracking, reimbursement signals, trade data, peer-reviewed evidence, public health indicators, and healthcare infrastructure analysis.
Insights are triangulated through demand-side and supply-side analysis, including device adoption patterns, procedure migration, hospital procurement behavior, regional access dynamics, regulatory pathways, and competitive positioning across urology endoscopy, stone treatment, catheters, urodynamics, BPH therapy, urinary incontinence care, oncologic urology, and surgical technologies.
The urology devices market is entering a phase defined by minimally invasive care, digital integration, infection prevention, and broader access to specialty treatment. Devices that improve procedural efficiency, patient safety, clinical workflow, and measurable outcomes will remain best positioned across hospitals, specialty clinics, and ambulatory surgery centers.
Long-term industry momentum will be driven by aging demographics, rising urologic disease burden, outpatient procedure migration, AI-enabled workflows, regulatory quality expectations, and regional healthcare investment. Companies that combine innovation with evidence, affordability, regulatory readiness, supply resilience, and physician training will be better positioned to build durable competitive advantage.